Skip to main content
Telix Pharmaceuticals Ltd logo

Telix Pharmaceuticals Ltd — Investor Relations & Filings

Ticker · TLX ISIN · AU000000TLX2 ASX Manufacturing
Open in API
Filings indexed 989 across all filing types
Latest filing 2022-11-06 Regulatory Filings
Country US United States of America
Listing ASX TLX

About Telix Pharmaceuticals Ltd

https://telixpharma.com/

Telix Pharmaceuticals is a commercial-stage biopharmaceutical company focused on the development and commercialization of diagnostic and therapeutic radiopharmaceuticals, an approach known as 'theranostics'. The company utilizes targeted radiation to both image and treat various forms of cancer. Its extensive clinical pipeline and portfolio address key areas in oncology, including urologic (prostate and kidney), neurologic (glioma), and musculoskeletal cancers, as well as applications in bone marrow conditioning. Telix has secured global regulatory approvals for its prostate cancer imaging agent and supports its products with a robust global supply, manufacturing, and distribution network. The company is actively engaged in numerous clinical trials worldwide to expand its theranostic platform.

Recent filings

Filing Released Lang Actions
Cleansing Notice 1 page 162.0KB
Regulatory Filings Classification · 95% confidence The document is a notice under section 708A(5)(e) of the Corporations Act 2001, referencing the issuance of shares upon exercise of options and compliance with disclosure requirements. It is a regulatory announcement about share issuance and compliance, not a full financial report or detailed capital update. The document length is short (1364 characters) and it serves as a formal notification rather than a report or presentation. This fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2022-11-06 English
Notification regarding unquoted securities - TLX 7 pages 31.3KB
Capital/Financing Update Classification · 100% confidence The document is titled 'Notification of Issue, Conversion or Payment up of Unquoted Equity Securities' and details the issuance of unquoted securities under an employee incentive scheme by Telix Pharmaceuticals Limited. It includes specifics such as the number of securities issued, the type of securities (Share Appreciation Rights), issue dates, and references to ASX listing rules. The document is a formal announcement of a securities issuance event rather than a financial report or earnings release. It does not contain financial statements or management discussion but focuses on capital changes related to securities issuance. Therefore, it fits the category of Capital/Financing Update (CAP). The document length (7737 characters) supports it being a full announcement rather than a brief notice or report publication announcement.
2022-10-25 English
Notification of cessation of securities - TLX 5 pages 27.0KB
Regulatory Filings Classification · 95% confidence The document is titled 'Notification of cessation of +securities' and details the lapse or forfeiture of certain securities (options and share appreciation rights) due to conditions not being met or termination of employment. It provides specific information about the securities that have ceased, the reasons for cessation, and the updated issued capital following these changes. The document is an announcement about changes in the company's issued securities, specifically the cessation of certain securities. It does not contain financial statements, audit information, or detailed financial results. It is not a report but an official notification to the market about changes in securities. This fits best under the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2022-10-24 English
Appendix 4C and Activities Report - September 2022 Quarter 10 pages 247.3KB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'APPENDIX 4C QUARTERLY CASH FLOW AND ACTIVITIES REPORT FOR PERIOD ENDED 30 SEPTEMBER 2022' and contains detailed financial data and operational updates for the quarter ended 30 September 2022. It includes revenue figures, cash flow statements, commercial activity reports, regulatory updates, and clinical trial progress. The presence of actual financial data and substantive analysis for a quarterly period indicates this is a comprehensive interim financial report. The document is approximately 15,000 characters long, which supports it being a full report rather than a brief announcement. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q3 2022
2022-10-19 English
Q3 2022 Business Update to accompany quarterly results 17 pages 1.9MB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Q3 2022 Quarterly Business Update Telix Pharmaceuticals' and dated 20 October 2022. It contains detailed financial metrics for Q3 2022, including revenue, cash flow, operating expenditure, and sales performance. The content includes forward-looking statements, commercial sales data, pipeline updates, and financial commentary specific to the quarter ending September 2022. The document is approximately 15,000 characters long, indicating it is a substantive report rather than a brief announcement. The presence of quarterly financial data and business updates aligns with the characteristics of an Interim / Quarterly Report (IR). There is no indication that this is a full annual report, audit report, or earnings release (which typically are shorter and more headline-focused). It is not a presentation or transcript, nor is it a regulatory filing or announcement. Therefore, the document is best classified as an Interim / Quarterly Report (IR). Q3 2022
2022-10-19 English
TLX250-CDx Indication Expansion - Preliminary Data 5 pages 238.0KB
Regulatory Filings Classification · 95% confidence The document is an ASX release from Telix Pharmaceuticals Limited announcing preliminary data from two investigator-initiated clinical studies (OPALESCENCE and PERTINENCE) related to their product TLX250-CDx. It contains detailed descriptions of study objectives, preliminary results, and scientific context. The document is not a full financial report, audit, or regulatory filing. It is not a transcript of a call, nor a management or investor presentation. It is a corporate announcement of clinical study data, which fits best under the category of a Capital/Financing Update (CAP) or Regulatory Filings (RNS). However, since it is an ASX release announcing clinical data and not financial or capital structure updates, the best fit is Regulatory Filings (RNS) as a general announcement category for such disclosures. The document length (15,000 characters) and content confirm it is a full announcement, not a brief report publication notice or certification. Therefore, the classification is RNS with high confidence.
2022-10-17 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.